

**AMENDMENTS TO THE CLAIMS**

The following claim listing supersedes all prior claim listings in the application.

**Claims 1-10 (cancelled)**

11. (currently amended) A conjugated vaccine comprising an antigen that has been conjugated to Fragment C,  
wherein the Fragment C does not exist in the conjugate vaccine as part of a whole tetanus toxoid molecule, and

wherein the conjugate vaccine does not increase a patient's anti-tetanus titer response.

12. (original) The conjugated vaccine according to claim 11, wherein the antigen is a capsular polysaccharide from a bacterium.

13. (original) The conjugated vaccine according to claim 12, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1, 2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.

**Claims 14 and 15 (cancelled)**

16. (new) The conjugate vaccine according to claim 11, wherein the Fragment C is obtained by recombinant expression.
17. (new) The conjugate vaccine according to claim 11, wherein the Fragment C is obtained from a tetanus toxoid molecule via digestion of the tetanus toxoid molecule by a protease.
18. (new) The conjugate vaccine according to claim 11, wherein the protease is papain.
19. (new) The conjugate vaccine according to claim 13, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X.
20. (new) The conjugate vaccine according to claim 13, wherein the bacterium is selected from the group consisting of Streptococcus group A, B, and C.
21. (new) The conjugate vaccine according to claim 13, wherein the bacterium is selected from the group consisting of Pneumococcus types 1, 2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23.
22. (new) The conjugate vaccine according to claim 13, wherein the bacterium is selected from the group consisting of Staphylococcus aureus types 5 and 8.
23. (new) The conjugate vaccine according to claim 13, wherein the bacterium is Haemophilus influenzae type b.

24. (new) The conjugated vaccine according to claim 12, wherein the bacterium is selected from the group consisting of *Mycobacterium tuberculosis*; *Campylobacter* spp.; *Escherichia coli*; *Salmonella typhii*; *Vibrio cholerae*; *Shigella flexneri*; *Brucella* spp.; *Francicella tularensis*; and *Yersinia pestis*.
25. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Mycobacterium tuberculosis*.
26. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Escherichia coli*.
27. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Salmonella typhii*.
28. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Vibrio cholerae*.
29. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Shigella flexneri*.
30. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Brucella* spp.

31. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Francicella tularensis*.
32. (new) The conjugated vaccine according to claim 24, wherein the bacterium is *Yersinia pestis*.